You are here

CAR-T

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Drugs.com

Wed, 04/16/25 - 10:55 pm

systemic lupus erythematosus

idiopathic inflammatory myopathy

diffuse systemic sclerosis

BioNTech passes on Autolus’ CD19/CD22 CAR-T amid pipeline prioritization

Fierce Biotech

Thu, 03/20/25 - 11:13 am

Autolus Therapeutics

The key factors shaping China’s biopharma boom

Pharma Voice

Thu, 03/20/25 - 09:57 am

Atara, reeling from FDA hold on Ebvallo, lays off half of workforce

Fierce Biotech

Tue, 03/4/25 - 09:59 am

Atara Biotherapeutics

Otsuka breaks up with cancer candidates on strategic grounds

Fierce Biotech

Fri, 02/14/25 - 09:22 am

Galapagos drops one CD19 CAR-T to focus on 'flagship' program

Fierce Biotech

Thu, 02/13/25 - 09:48 pm

Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead

Fierce Pharma

Mon, 02/10/25 - 10:14 am

Bristol Myers Squibb

marginal zone lymphoma

Gilead Sciences

BrainChild Bio advances development of CAR T therapy for pediatric brain tumors

Biopharma Reporter

Tue, 01/7/25 - 11:21 am

CARsgen gets a win for CAR-T in solid tumors

Pharmaphorum

Fri, 01/3/25 - 09:55 am

Can CAR-T first movers keep pace in a rapidly evolving market?

Pharmaphorum

Wed, 12/11/24 - 10:59 am

Gilead Sciences

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing

Fierce Biotech

Wed, 11/20/24 - 08:44 pm

Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval

Fierce Biotech

Thu, 11/14/24 - 11:14 am

relapsed or refractory chronic lymphocytic leukemia

Autolus enters CAR-T race with FDA approval for Aucatzyl

Fierce Pharma

Mon, 11/11/24 - 11:49 am

Autolus Therapeutics

Gilead Sciences

relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

Fierce Pharma

Thu, 11/7/24 - 11:29 am

Gilead Sciences

Cellectis drops one of its 3 clinical-stage CAR-Ts

Fierce Biotech

Tue, 11/5/24 - 06:19 pm

Pharma 'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says

Fierce Pharma

Fri, 11/1/24 - 11:14 am

After scoring a first for an off-the-shelf CAR-T, can Atara maintain momentum?

Pharma Voice

Mon, 09/30/24 - 09:17 am

Atara Biotherapeutics

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

BioPharma Dive

Mon, 09/16/24 - 10:14 pm

Kyverna Therapeutics

Gilead Sciences

Orgenesis touts early clinical promise of CAR-T therapy with decentralized production in mind

Biopharma Reporter

Tue, 09/3/24 - 11:16 am

clinical trials

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats

Investors Business Daily

Mon, 08/26/24 - 11:11 am

non-Hodgkin lymphoma

Gilead Sciences

Pages